View in EDS HTML Full Text PDF Full Text

Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain.

Saved in:
Bibliographic Details
Title: Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain.
Authors: Strzelczyk, Adam (AUTHOR), Knake, Susanne (AUTHOR), Kälviäinen, Reetta (AUTHOR), Santamarina, Estevo (AUTHOR), Toledo, Manuel (AUTHOR), Willig, Sophia (AUTHOR), Rohracher, Alexandra (AUTHOR), Trinka, Eugen (AUTHOR), Rosenow, Felix (AUTHOR)
Source: Acta Neurologica Scandinavica. Apr2019, Vol. 139 Issue 4, p369-376. 8p.
Subjects: Status epilepticus
Geographic Terms: Austria, Finland, Spain
Abstract: Objective: Novel treatments are needed to control treatment‐resistant status epilepticus (SE). We report a summary of clinical cases where perampanel was used in established SE, refractory SE (RSE), or super‐refractory SE (SRSE). Methods: Medical records were retrospectively reviewed for perampanel administration in SE at five European hospitals between 2011 and 2015. Results: Of 1319 patients identified as experiencing SE, 52 (3.9%) received perampanel. Median latency from SE onset to perampanel initiation was 10 days. Patients with SE had previously failed benzodiazepines (when received) and a median of five other antiepileptic drugs (AEDs). Median initial perampanel dose was 6 mg/d, up‐titrated to a median maximum dose of 10 mg/d. Perampanel was the last drug added in 32/52 (61.5%) patients, with response attributed to perampanel in 19/52 (36.5%) patients. A greater proportion of perampanel non‐responders had SRSE (51.5%; 17/33) vs perampanel responders (31.6%; 6/19), and had failed a higher mean number of AEDs before initiating perampanel (5.9 vs 5.1, respectively). Most commonly reported adverse effects during perampanel treatment were dizziness (n = 1 [1.9%]) and somnolence (n = 1 [1.9%]). No serious adverse effects were documented, and none led to discontinuation of perampanel. Conclusions: Perampanel was administered to patients with established SE, RSE, or SRSE at greater initial doses than those administered in clinical practice to patients with epilepsy. The SE cases reported here represent a refractory and heterogeneous population, and rate of seizure cessation attributed to perampanel treatment (36.5%) represents a notable response. These data should be confirmed in a larger patient population. [ABSTRACT FROM AUTHOR]
Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 135292766
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Strzelczyk%2C+Adam%22">Strzelczyk, Adam</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Knake%2C+Susanne%22">Knake, Susanne</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kälviäinen%2C+Reetta%22">Kälviäinen, Reetta</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Santamarina%2C+Estevo%22">Santamarina, Estevo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Toledo%2C+Manuel%22">Toledo, Manuel</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Willig%2C+Sophia%22">Willig, Sophia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rohracher%2C+Alexandra%22">Rohracher, Alexandra</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Trinka%2C+Eugen%22">Trinka, Eugen</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rosenow%2C+Felix%22">Rosenow, Felix</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Acta+Neurologica+Scandinavica%22">Acta Neurologica Scandinavica</searchLink>. Apr2019, Vol. 139 Issue 4, p369-376. 8p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Status+epilepticus%22">Status epilepticus</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Austria%22">Austria</searchLink><br /><searchLink fieldCode="DE" term="%22Finland%22">Finland</searchLink><br /><searchLink fieldCode="DE" term="%22Spain%22">Spain</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objective: Novel treatments are needed to control treatment‐resistant status epilepticus (SE). We report a summary of clinical cases where perampanel was used in established SE, refractory SE (RSE), or super‐refractory SE (SRSE). Methods: Medical records were retrospectively reviewed for perampanel administration in SE at five European hospitals between 2011 and 2015. Results: Of 1319 patients identified as experiencing SE, 52 (3.9%) received perampanel. Median latency from SE onset to perampanel initiation was 10 days. Patients with SE had previously failed benzodiazepines (when received) and a median of five other antiepileptic drugs (AEDs). Median initial perampanel dose was 6 mg/d, up‐titrated to a median maximum dose of 10 mg/d. Perampanel was the last drug added in 32/52 (61.5%) patients, with response attributed to perampanel in 19/52 (36.5%) patients. A greater proportion of perampanel non‐responders had SRSE (51.5%; 17/33) vs perampanel responders (31.6%; 6/19), and had failed a higher mean number of AEDs before initiating perampanel (5.9 vs 5.1, respectively). Most commonly reported adverse effects during perampanel treatment were dizziness (n = 1 [1.9%]) and somnolence (n = 1 [1.9%]). No serious adverse effects were documented, and none led to discontinuation of perampanel. Conclusions: Perampanel was administered to patients with established SE, RSE, or SRSE at greater initial doses than those administered in clinical practice to patients with epilepsy. The SE cases reported here represent a refractory and heterogeneous population, and rate of seizure cessation attributed to perampanel treatment (36.5%) represents a notable response. These data should be confirmed in a larger patient population. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=135292766
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ane.13061
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 369
    Subjects:
      – SubjectFull: Status epilepticus
        Type: general
      – SubjectFull: Austria
        Type: general
      – SubjectFull: Finland
        Type: general
      – SubjectFull: Spain
        Type: general
    Titles:
      – TitleFull: Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Strzelczyk, Adam
      – PersonEntity:
          Name:
            NameFull: Knake, Susanne
      – PersonEntity:
          Name:
            NameFull: Kälviäinen, Reetta
      – PersonEntity:
          Name:
            NameFull: Santamarina, Estevo
      – PersonEntity:
          Name:
            NameFull: Toledo, Manuel
      – PersonEntity:
          Name:
            NameFull: Willig, Sophia
      – PersonEntity:
          Name:
            NameFull: Rohracher, Alexandra
      – PersonEntity:
          Name:
            NameFull: Trinka, Eugen
      – PersonEntity:
          Name:
            NameFull: Rosenow, Felix
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: Apr2019
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 00016314
          Numbering:
            – Type: volume
              Value: 139
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Acta Neurologica Scandinavica
              Type: main
ResultId 1